Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Oncopeptides AB (publ) (ONCO.ST)
SEK1.60
-0.01 (-0.62%)
SE STO Healthcare Biotechnology
Address
Vastra Tradgardsgatan 15 111 53
Stockholm, SE
Stockholm, SE
CEO
Sofia Heigis
Website
oncopeptides.com/sv
IPO
2017-02-22
ISIN SE0009414576
Also trades on
Other OTC · ONPPF (USD)
Stockholm Stock Exchange · ONCO.ST (SEK)
Description
Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical therapies for cancer, serving markets across the United States, Europe, and worldwide. Its foremost experimental compound, melflufen, is a distinct peptide-drug conjugate engineered to address multiple myeloma that has relapsed or become resistant to prior treatments in adult individuals. Founded in 2000, Oncopeptides AB (publ) conducts its main business from Stockholm, Sweden.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
SEK1.60
-0.01 (-0.62%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6M
Beta
-1.31
Float Shares
174.68M
Free Float %
76.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.58% | +29.92% | +17.29% | -36.02% | -67.46% | -65.39% | -15.55% | -69.40% | -98.09% | -94.49% | -94.49% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1.60
Ratings Trend (MoM)
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-0.14
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+124.7% ★ Q1'26: +91.3% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+35.7% ★ Q1'26: +58.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-365.0% Q1'26: -214.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-321.8% Q1'26: -160.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +126.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+36.3% Q1'26: +28.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.55× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 6.13M (-100.0%)
|
118.30M
est: 155.53M (-23.9%)
|
8.36M
est: 15.57M (-46.3%)
|
35.22M
est: 21.37M (+64.8%)
|
31.65M
est: 34.32M (-7.8%)
|
71.12M
est: 78.50M (-9.4%)
|
160.50M
140.19M – 180.81M
+104.5% YoY
|
243.00M
199.49M – 286.51M
+51.4% YoY
|
529.96M
445.73M – 614.19M
+118.1% YoY
|
688.83M
579.35M – 798.31M
+30.0% YoY
|
| EBITDA |
-1.58B
est: -3.68M (-42,778.4%)
|
-1.40B
est: -93.32M (-1,399.2%)
|
-319.62M
est: -9.34M (-3,322.0%)
|
-231.62M
est: -21.37M (-983.9%)
|
-261.81M
est: -34.32M (-662.7%)
|
-228.82M
est: -78.50M (-191.5%)
|
-160.50M
-180.81M – -140.19M
-104.5% YoY
|
-243.00M
-286.51M – -199.49M
-51.4% YoY
|
-529.96M
-614.19M – -445.73M
-118.1% YoY
|
-688.83M
-798.31M – -579.35M
-30.0% YoY
|
| EBIT |
-1.59B
est: -3.68M (-43,170.2%)
|
-1.42B
est: -93.32M (-1,422.1%)
|
-336.80M
est: -9.34M (-3,506.0%)
|
-242.66M
est: -21.37M (-1,035.6%)
|
-271.55M
est: -34.32M (-691.1%)
|
-228.82M
est: -78.50M (-191.5%)
|
-160.50M
-180.81M – -140.19M
-104.5% YoY
|
-243.00M
-286.51M – -199.49M
-51.4% YoY
|
-529.96M
-614.19M – -445.73M
-118.1% YoY
|
-688.83M
-798.31M – -579.35M
-30.0% YoY
|
| Net Income |
-1.59B
est: -2.40B (+33.6%)
|
-1.43B
est: -1.91B (+25.0%)
|
-337.95M
est: -388.87M (+13.1%)
|
-249.11M
est: -262.70M (+5.2%)
|
-284.61M
est: -345.96M (+17.7%)
|
-249.59M
est: -221.10M (-12.9%)
|
-83.49M
-100.74M – -66.24M
+62.2% YoY
|
23.55M
18.68M – 28.41M
+128.2% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
654.19M
est: 45.34M (+1,343.0%)
|
873.81M
est: 1.15B (-24.1%)
|
142.20M
est: 115.17M (+23.5%)
|
188.48M
est: 165.51M (+13.9%)
|
197.28M
est: 265.86M (-25.8%)
|
194.62M
est: 608.02M (-68.0%)
|
1.24B
1.09B – 1.40B
+104.5% YoY
|
1.88B
1.55B – 2.22B
+51.4% YoY
|
4.10B
3.45B – 4.76B
+118.1% YoY
|
5.34B
4.49B – 6.18B
+30.0% YoY
|
| EPS |
-25.57
est: -14.42 (-77.3%)
|
-19.00
est: -11.46 (-65.8%)
|
-4.11
est: -2.34 (-75.9%)
|
-1.96
est: -1.22 (-60.5%)
|
-1.71
est: -1.52 (-12.1%)
|
-1.10
est: -0.99 (-11.0%)
|
-0.37
-0.44 – -0.29
+62.9% YoY
|
0.10
0.08 – 0.13
+128.2% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-303.23M
OE per share TTM
-1.45
Owner's Yield
-66.90%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
68.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-28.6K
Shares Outstanding
227.21M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sofia Heigis | Chief Executive Officer | 7M | female |
| Jakob Lindberg Med. Lic | Chief Scientific Officer | 5M | — |
| Hans Ehrsson | Founder | — | — |
| Henrik Bergentoft | Chief Financial Officer | — | male |
| David Augustsson | Director of IR, Communications & Corporate Affairs | — | male |
| Kristina Luthman | Founder | — | — |
| Peter Nygren | Founder | — | male |
| Rolf Larsson | Founder | — | — |
| Rolf Lewensohn | Founder | — | — |
| Joachim Gullbo | Founder | — | — |
| Eva Nordström | Chief Operating Officer & Deputy MD | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ONCO.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
